echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Stem Cell Research & Therapy: miR-424-5p can be used as a biomarker for early heart disease

    Stem Cell Research & Therapy: miR-424-5p can be used as a biomarker for early heart disease

    • Last Update: 2021-05-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    medsci.


    medsci.


    Type 1 Diabetes Diabetes is a case of the pancreas does not produce enough insulin or does not produce insulin, resulting in elevated blood sugar levels of the disease .


     A study published in the " stem cell research and treatment " ( Stem the Cell Research, ) study showed that , in patients with type 1 diabetes often give the diagnosis may have characteristics of premature heart disease induced by the disorder before.


     A study published in the " stem cell research stem cell research stem cells and treatment " ( Stem the Cell Research, Stem the Cell Research, ) studies show , type 1 diabetes often give the diagnosis may have characteristics induced by the disorder of premature heart before.


    In this cross-sectional study, the researchers recruited 29 T1DM patients and 20 healthy subjects of age and gender matching.


    In this cross-sectional study, the researchers recruited 29 T1DM patients and 20 healthy subjects of age and gender matching.


    Participants after an overnight fast, researchers collected from peripheral blood samples of all participants , for the evaluation of different levels of the study group of angiogenic cytokines and markers.


     The results of the study found that MiR-424-5p was up-regulated in T1DM in PBMC ( p p<0.


     In contrast , vascular health-fibronectin, pro-angiogenic cells and CD45dim CD34+ 133+ cell content decreased in T1DM , so T1DM will show impaired vascular repair.


     In contrast , vascular health-fibronectin, pro-angiogenic cells and CD45dim CD34+ 133+ cell content decreased in T1DM , so T1DM will show impaired vascular repair.


    MiR-424-5p wasnegatively correlated with cEPC, PAC (and FAA ( p <0.


    MiR-424-5pis negatively correlated with cEPC, PAC (and FAA ( p p <0.


    ROC curve analysis showed that (1) miR-424-5p is a biomarker of T1DM ( p p   <0.


     

    In summary , the researchers verified the anti-angiogenic properties of miR-424-5p in animal studies in T1DM.


    In summary , the researchers verified the anti-angiogenic properties of miR-424-5p in animal studies in T1DM.


    Therefore, miR-424-5p has potential use in CVD monitoring, and anti-miR-424-5p-based therapies can be used to reduce CVD morbidity/mortality in T1DM.

     

     

    references:

    references:

    Upregulated anti-angiogenic miR-424-5p in type 1 diabetes (model of subclinical cardiovascular disease) correlates with endothelial progenitor cells,  CXCR1/2  and other parameters of vascular health 

    Upregulated anti-angiogenic miR-424-5p in type 1 diabetes (model of subclinical cardiovascular disease) correlates with endothelial progenitor cells,  CXCR1/2  and other parameters of vascular health CXCR1/2 

     

     

     

     

     

     Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.